Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 27 | 2021 | 443 | 2.050 |
Why?
|
| Lung Neoplasms | 9 | 2020 | 423 | 0.940 |
Why?
|
| Breast Neoplasms | 12 | 2019 | 762 | 0.900 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2020 | 17 | 0.650 |
Why?
|
| Antibodies, Monoclonal | 10 | 2019 | 245 | 0.520 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2012 | 108 | 0.490 |
Why?
|
| Colorectal Neoplasms | 6 | 2016 | 219 | 0.460 |
Why?
|
| Aged | 39 | 2021 | 10263 | 0.420 |
Why?
|
| Middle Aged | 39 | 2021 | 11851 | 0.390 |
Why?
|
| Taxoids | 7 | 2018 | 50 | 0.390 |
Why?
|
| Triazoles | 3 | 2017 | 15 | 0.380 |
Why?
|
| Nitriles | 3 | 2017 | 24 | 0.380 |
Why?
|
| Aged, 80 and over | 23 | 2021 | 3900 | 0.350 |
Why?
|
| Disease-Free Survival | 14 | 2018 | 324 | 0.350 |
Why?
|
| Aminopyridines | 4 | 2019 | 6 | 0.330 |
Why?
|
| Purines | 4 | 2019 | 21 | 0.330 |
Why?
|
| Immunoconjugates | 3 | 2019 | 10 | 0.320 |
Why?
|
| Adult | 29 | 2019 | 9259 | 0.310 |
Why?
|
| Pyrimidines | 3 | 2020 | 77 | 0.310 |
Why?
|
| Female | 37 | 2021 | 19945 | 0.290 |
Why?
|
| Multiple Myeloma | 2 | 2021 | 24 | 0.280 |
Why?
|
| Humans | 41 | 2021 | 32282 | 0.280 |
Why?
|
| Treatment Outcome | 20 | 2019 | 3416 | 0.270 |
Why?
|
| Double-Blind Method | 5 | 2020 | 565 | 0.250 |
Why?
|
| Nanoparticles | 2 | 2018 | 52 | 0.250 |
Why?
|
| Sirolimus | 4 | 2014 | 34 | 0.250 |
Why?
|
| Receptor, erbB-2 | 6 | 2018 | 63 | 0.240 |
Why?
|
| Salvage Therapy | 2 | 2021 | 135 | 0.240 |
Why?
|
| Adenocarcinoma | 4 | 2015 | 298 | 0.230 |
Why?
|
| Neoplasm Metastasis | 9 | 2019 | 222 | 0.220 |
Why?
|
| Male | 29 | 2021 | 19441 | 0.220 |
Why?
|
| Neoplasm Staging | 9 | 2019 | 461 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Neoplasms | 3 | 2016 | 754 | 0.200 |
Why?
|
| Mutation | 2 | 2018 | 497 | 0.190 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 595 | 0.180 |
Why?
|
| Maximum Tolerated Dose | 6 | 2021 | 62 | 0.180 |
Why?
|
| Receptors, Estrogen | 6 | 2017 | 104 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2018 | 90 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Prostate-Specific Antigen | 2 | 2018 | 59 | 0.170 |
Why?
|
| Topotecan | 1 | 2020 | 14 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2016 | 16 | 0.160 |
Why?
|
| Quinazolines | 5 | 2012 | 35 | 0.160 |
Why?
|
| Postmenopause | 4 | 2017 | 424 | 0.160 |
Why?
|
| Membrane Glycoproteins | 3 | 2019 | 111 | 0.160 |
Why?
|
| Pyrroles | 1 | 2020 | 59 | 0.160 |
Why?
|
| Benzamides | 2 | 2018 | 60 | 0.160 |
Why?
|
| Receptors, Progesterone | 5 | 2017 | 50 | 0.150 |
Why?
|
| Imidazoles | 3 | 2015 | 97 | 0.150 |
Why?
|
| Androstadienes | 3 | 2013 | 15 | 0.150 |
Why?
|
| Survival Rate | 8 | 2019 | 893 | 0.150 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2018 | 2 | 0.150 |
Why?
|
| CREB-Binding Protein | 1 | 2018 | 4 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 13 | 0.140 |
Why?
|
| Camptothecin | 5 | 2016 | 45 | 0.140 |
Why?
|
| Drug Administration Schedule | 5 | 2021 | 276 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 67 | 0.140 |
Why?
|
| Leukopenia | 1 | 2017 | 9 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 30 | 0.130 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 2 | 2015 | 3 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 258 | 0.130 |
Why?
|
| Melanoma | 1 | 2019 | 166 | 0.130 |
Why?
|
| Naphthalenes | 2 | 2015 | 53 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 40 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 220 | 0.120 |
Why?
|
| Quality of Life | 2 | 2020 | 964 | 0.120 |
Why?
|
| Pyrrolidinones | 1 | 2016 | 6 | 0.120 |
Why?
|
| Quinolines | 1 | 2016 | 29 | 0.120 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2016 | 8 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2016 | 22 | 0.120 |
Why?
|
| Resorcinols | 1 | 2015 | 7 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 7 | 0.120 |
Why?
|
| Isoxazoles | 1 | 2015 | 7 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 106 | 0.120 |
Why?
|
| Organoplatinum Compounds | 4 | 2012 | 41 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2013 | 7 | 0.100 |
Why?
|
| ras Proteins | 2 | 2012 | 10 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2012 | 83 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 381 | 0.100 |
Why?
|
| Bone Remodeling | 1 | 2013 | 9 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 1 | 2013 | 23 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 773 | 0.090 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2012 | 2 | 0.090 |
Why?
|
| Pyridones | 1 | 2012 | 10 | 0.090 |
Why?
|
| Pyrimidinones | 1 | 2012 | 7 | 0.090 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2012 | 4 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 131 | 0.090 |
Why?
|
| Bone Density | 1 | 2013 | 169 | 0.090 |
Why?
|
| Prognosis | 4 | 2019 | 1534 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2014 | 34 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 117 | 0.090 |
Why?
|
| Nausea | 3 | 2018 | 49 | 0.090 |
Why?
|
| Fatigue | 3 | 2018 | 76 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2240 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 120 | 0.080 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 3 | 0.080 |
Why?
|
| Lymphoma, Follicular | 1 | 2009 | 17 | 0.080 |
Why?
|
| Oligopeptides | 2 | 2021 | 49 | 0.070 |
Why?
|
| Disease Progression | 3 | 2015 | 591 | 0.070 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 21 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 40 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2007 | 113 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2006 | 77 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2006 | 86 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 717 | 0.060 |
Why?
|
| Diarrhea | 2 | 2018 | 56 | 0.060 |
Why?
|
| Carboplatin | 3 | 2012 | 42 | 0.060 |
Why?
|
| Deoxycytidine | 3 | 2013 | 57 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2007 | 200 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2018 | 165 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 187 | 0.050 |
Why?
|
| Leucovorin | 3 | 2012 | 19 | 0.050 |
Why?
|
| Young Adult | 3 | 2019 | 2649 | 0.050 |
Why?
|
| Fluorouracil | 3 | 2012 | 79 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 854 | 0.050 |
Why?
|
| Pyrazines | 2 | 2014 | 14 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2012 | 57 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 2205 | 0.040 |
Why?
|
| Premedication | 1 | 2021 | 15 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 20 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 50 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2010 | 22 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 20 | 0.040 |
Why?
|
| Guanine | 2 | 2007 | 14 | 0.030 |
Why?
|
| Glutamates | 2 | 2007 | 10 | 0.030 |
Why?
|
| Breast | 1 | 2017 | 63 | 0.030 |
Why?
|
| Dyspnea | 1 | 2017 | 32 | 0.030 |
Why?
|
| Arthralgia | 1 | 2017 | 29 | 0.030 |
Why?
|
| Mastectomy | 1 | 2017 | 59 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 168 | 0.030 |
Why?
|
| Hot Flashes | 1 | 2017 | 49 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2016 | 25 | 0.030 |
Why?
|
| New Zealand | 1 | 2015 | 6 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 19 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 25 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 35 | 0.030 |
Why?
|
| North America | 1 | 2015 | 31 | 0.030 |
Why?
|
| United States | 3 | 2012 | 4072 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 21 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 42 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 82 | 0.030 |
Why?
|
| Prednisone | 1 | 2015 | 69 | 0.030 |
Why?
|
| Indoles | 1 | 2015 | 65 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2014 | 15 | 0.030 |
Why?
|
| Neutropenia | 1 | 2014 | 24 | 0.030 |
Why?
|
| Anemia | 1 | 2014 | 50 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1241 | 0.030 |
Why?
|
| Alopecia | 1 | 2014 | 29 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 6 | 0.030 |
Why?
|
| Depression | 1 | 2017 | 420 | 0.030 |
Why?
|
| Viscera | 1 | 2013 | 13 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2013 | 12 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 27 | 0.020 |
Why?
|
| Stomatitis | 1 | 2013 | 18 | 0.020 |
Why?
|
| Placebos | 1 | 2013 | 68 | 0.020 |
Why?
|
| Exanthema | 1 | 2013 | 19 | 0.020 |
Why?
|
| Procollagen | 1 | 2013 | 7 | 0.020 |
Why?
|
| Fractures, Spontaneous | 1 | 2013 | 12 | 0.020 |
Why?
|
| Bone Resorption | 1 | 2013 | 11 | 0.020 |
Why?
|
| Aromatase Inhibitors | 1 | 2013 | 8 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 40 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 110 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 545 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2013 | 44 | 0.020 |
Why?
|
| Albumins | 1 | 2012 | 42 | 0.020 |
Why?
|
| Anilides | 1 | 2012 | 12 | 0.020 |
Why?
|
| Epothilones | 1 | 2012 | 3 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2013 | 79 | 0.020 |
Why?
|
| Half-Life | 1 | 2012 | 24 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 18 | 0.020 |
Why?
|
| Pyridines | 1 | 2012 | 79 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 90 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 30 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 312 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 200 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 456 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 252 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 38 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 541 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 113 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 36 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 43 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 979 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2009 | 9 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 308 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2007 | 4 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2007 | 3 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2007 | 3 | 0.020 |
Why?
|
| Piperazines | 1 | 2007 | 60 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 3934 | 0.020 |
Why?
|
| Heart Failure | 1 | 2013 | 728 | 0.020 |
Why?
|
| Cisplatin | 1 | 2006 | 78 | 0.020 |
Why?
|
| Adolescent | 1 | 2014 | 3519 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2006 | 477 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 3626 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 2571 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 8199 | 0.010 |
Why?
|